| scholarly article | Q13442814 |
| P2093 | author name string | Alexei Kharitonenkov | |
| James D Dunbar | |||
| Radmila Micanovic | |||
| Shun Li | |||
| Christine C Cheng | |||
| David E Moller | |||
| Tamer Coskun | |||
| Anja Koester | |||
| Christopher C Frye | |||
| Beth A Strifler | |||
| John M Beals | |||
| Victor J Wroblewski | |||
| Thomas F Bumol | |||
| Amy M Ford | |||
| Radhakrishnan Rathnachalam | |||
| P2860 | cites work | Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys | Q46844955 |
| Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor | Q48694793 | ||
| Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency | Q56902099 | ||
| Solvent effects on the solubility and physical stability of human insulin-like growth factor I | Q73371162 | ||
| Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry | Q74383152 | ||
| Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21 | Q84079985 | ||
| [Optimization and characterization of a novel FGF21 mutant] | Q85001479 | ||
| Identification of a novel FGF, FGF-21, preferentially expressed in the liver | Q22254289 | ||
| betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c | Q24306279 | ||
| Different roles of N- and C- termini in the functional activity of FGF21 | Q24312210 | ||
| FGF21 N- and C-termini play different roles in receptor interaction and activation | Q24322074 | ||
| FGF-21 as a novel metabolic regulator | Q24523933 | ||
| Lessons from the lysozyme of phage T4 | Q24623930 | ||
| BetaKlotho is required for metabolic activity of fibroblast growth factor 21 | Q24681531 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| FGF21 requires βklotho to act in vivo | Q28485347 | ||
| Fundamentals of FGF19 & FGF21 action in vitro and in vivo | Q28729024 | ||
| Applications of yeast in biotechnology: protein production and genetic analysis | Q33744864 | ||
| The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. | Q34577053 | ||
| Fibroblast growth factor 21 corrects obesity in mice | Q34805555 | ||
| Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes | Q35266423 | ||
| Recombinant expression systems in the pharmaceutical industry | Q35916340 | ||
| Peroxisomal targeting, import, and assembly of alcohol oxidase in Pichia pastoris | Q36254940 | ||
| Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease | Q37781747 | ||
| Immunogenicity of protein aggregates--concerns and realities | Q38006563 | ||
| Metabolic disease drug discovery- "hitting the target" is easier said than done | Q39666960 | ||
| FGF21 reloaded: challenges of a rapidly growing field | Q39798117 | ||
| FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents | Q40667176 | ||
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue | Q41912342 | ||
| FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho | Q42819634 | ||
| Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling | Q42834234 | ||
| Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice | Q43224118 | ||
| Introduction to Pichia pastoris | Q45888519 | ||
| The effect of benzyl alcohol on recombinant human interferon-gamma | Q46186532 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e58575 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319 | |
| P478 | volume | 8 |
| Q38707493 | A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development |
| Q102144619 | AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients |
| Q37448127 | An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function |
| Q34247340 | Autophagy and non-alcoholic fatty liver disease. |
| Q36611366 | Circulating FGF21 proteolytic processing mediated by fibroblast activation protein |
| Q33808884 | Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. |
| Q104073661 | Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects |
| Q43639041 | Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo |
| Q50858150 | FAP finds FGF21 easy to digest. |
| Q98906651 | FGF/FGFR signaling in health and disease |
| Q35830589 | FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance |
| Q37485018 | FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice |
| Q37211913 | FGF21 mimetic shows therapeutic promise. |
| Q36674741 | Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21 |
| Q38794405 | Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus |
| Q39325845 | Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. |
| Q26772751 | Fibroblast Growth Factor Signaling in Metabolic Regulation |
| Q41166927 | Fibroblast activation protein (FAP) as a novel metabolic target |
| Q35387801 | Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes |
| Q64889156 | Fibroblast growth factor 21 in chronic kidney disease. |
| Q35784028 | Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes |
| Q39017842 | Fibroblast growth factor 21 night watch: advances and uncertainties in the field |
| Q64973345 | Fibroblast growth factors 19 and 21 in acute liver damage. |
| Q52649955 | Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. |
| Q51730495 | Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing. |
| Q92707454 | Hepatic posttranscriptional network comprised of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis |
| Q61443294 | High-efficiency expression and secretion of human FGF21 in Bacillus subtilis by intercalation of a mini-cistron cassette and combinatorial optimization of cell regulatory components |
| Q28550659 | Human FGF-21 Is a Substrate of Fibroblast Activation Protein |
| Q64111598 | Inducible Loss of the Aryl Hydrocarbon Receptor Activates Perigonadal White Fat Respiration and Brown Fat Thermogenesis via Fibroblast Growth Factor 21 |
| Q53807997 | Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway. |
| Q26823319 | Inventing new medicines: The FGF21 story |
| Q34792753 | LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys |
| Q50000450 | LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice |
| Q38475978 | Latest approaches for the treatment of obesity. |
| Q26781427 | Metabolic Effects of FGF-21: Thermoregulation and Beyond |
| Q33685319 | Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues |
| Q36107291 | Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases |
| Q38397340 | New perspectives on the development of antiobesity drugs |
| Q47209022 | Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. |
| Q37112476 | PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. |
| Q35581474 | Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice |
| Q47742925 | Process development of a FGF21 protein-antibody conjugate. |
| Q47151186 | Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein. |
| Q33835303 | Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster. |
| Q89497203 | Role of Hepatokines in Non-alcoholic Fatty Liver Disease |
| Q50001768 | Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling |
| Q38852204 | Targeting adipose tissue in the treatment of obesity-associated diabetes |
| Q30234616 | The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes |
| Q98238156 | The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q91753933 | YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity |
Search more.